• ENO1, Macrophage Metabolism, and Cardiac Repair

  2026-11-03

  A preclinical study examines ENO1 as a metabolic regulator of inflammatory macrophages after myocardial infarction and tests an acid-responsive nanocarrier for localized siRNA delivery. Its findings connect glycolytic remodeling, lactate-associated signaling, macrophage state, and structural cardiac outcomes while leaving important questions about mechanism, model translation, and longer-term safety.

• ENO1, Macrophage Metabolism, and Cardiac Repair

  2026-11-03

  A preclinical study connects ENO1-driven glycolytic remodeling in post-infarction macrophages with inflammatory polarization and evaluates an acid-responsive siRNA nanocarrier as a mechanistic intervention. The findings support a proposed ENO1–lactate–KLF4 pathway while remaining limited to cellular and murine models.

• ENO1, Macrophage Metabolism, and Cardiac Repair

  2026-11-02

  A preclinical study examined whether ENO1 links post-infarction macrophage metabolism to inflammatory polarization and cardiac repair. Its findings support an acid-responsive nanocarrier strategy for localized ENO1 silencing, while remaining bounded by the use of cellular and murine models.

• ENO1, Macrophage Metabolism and Cardiac Repair

  2026-11-02

  A paper-centred interpretation of a preclinical study linking ENO1-dependent glycolytic remodeling in post-infarction macrophages with inflammatory polarization and cardiac repair, while examining an acid-responsive nanocarrier as a mechanistic delivery system.

• ENO1, Macrophage Metabolism, and Cardiac Repair

  2026-11-01

  A preclinical study links ENO1-dependent glycolytic remodeling to inflammatory macrophage behavior after myocardial infarction and evaluates an acid-responsive nanocarrier for localized siRNA delivery. The findings support a metabolism–lactate–KLF4 framework for macrophage regulation, while remaining bounded by experimental models and selected safety assessments.

• ENO1, Macrophage Metabolism and Cardiac Repair

  2026-10-31

  A paper-centred interpretation of a preclinical study examining ENO1 as a metabolic regulator of post-infarction macrophage behaviour and evaluating an acid-responsive siRNA nanocarrier in cellular and murine models.

• ENO1, Macrophage Metabolism, and Cardiac Repair

  2026-10-30

  A preclinical study examines ENO1 as a metabolic regulator of inflammatory macrophages after myocardial infarction and evaluates an acid-responsive siRNA nanocarrier as a mechanistic research tool. The findings connect ENO1 silencing with altered glycolysis, lactate–KLF4 signaling, macrophage state, and cardiac injury-associated readouts.

• SIRT1, Type H Vessels, and Bone Aging

  2026-10-30

  A preclinical study connects age-related loss of SIRT1 with reduced type H vasculature, osteogenic support, and endothelial–mesenchymal communication. Its cell, signaling, and mouse data support a coordinated SIRT1–β-catenin model, while sex, vascular-subtype, and biomechanical limits constrain interpretation.

• When Apoptosis Signals Change Meaning

  2026-10-29

  Annexin V fluorescence is most informative when interpreted as a context-dependent measure of cell-surface phosphatidylserine exposure. The post-infarction ENO1 study shows how an apoptosis-associated readout gains or loses meaning depending on cell type, disease stage, comparator, and the upstream metabolic mechanism being tested.

• ENO1, Macrophage Metabolism, and Cardiac Repair

  2026-10-29

  A preclinical study examined whether ENO1 links postinfarction macrophage metabolism to inflammatory polarization and whether an acid-responsive nanocarrier could test that mechanism in cellular and murine models. The reported findings connect ENO1 silencing with altered glycolysis, lactate signaling, macrophage state, and measures of cardiac remodeling, while leaving important questions about translation, durability, and mechanism-specificity.

• When an Apoptosis Signal Changes Meaning

  2026-10-28

  An Annexin V fluorescence signal is a measurement of cell-surface phosphatidylserine exposure, not an apoptosis diagnosis by itself. In the post-infarction ENO1 study, that distinction matters: annexin V belonged to the apoptosis-measurement layer, whereas the causal argument rested on macrophage metabolism, ENO1 perturbation, inflammatory markers, tissue remodeling, and ventricular function. The meaning of the result therefore changed with the model, comparator, endpoint, and biological context.

• ENO1, Macrophage Metabolism, and Cardiac Repair

  2026-10-28

  This preclinical study examines whether ENO1 links glycolytic remodeling with inflammatory macrophage behavior after myocardial infarction and tests an acid-responsive nanocarrier for macrophage-directed siRNA delivery. The reported findings connect ENO1 silencing with reduced inflammatory signaling, altered lactate–KLF4 regulation, and improved structural and functional cardiac outcomes in mice, while leaving important model-specific uncertainties.

• ENO1, Macrophage Metabolism, and Cardiac Repair

  2026-10-27

  A 2026 study identified ENO1 as a metabolic regulator linking postinfarction macrophage glycolysis to lactate accumulation, KLF4 suppression, inflammatory polarization, and impaired cardiac repair. Its evidence combined mouse and human transcriptomic data, cellular perturbation studies, mechanistic rescue experiments, and an in vivo responsive delivery system. This editorial explains what the study established, how cardiomyocyte apoptosis fits into the evidence chain, and why an Annexin V-based apoptosis assay should be interpreted as a downstream phosphatidylserine readout rather than as proof of the upstream ENO1–lactate–KLF4 mechanism.

• What Does a GLUT4 Antibody Signal Mean?

  2026-10-27

  A GLUT4 antibody can show that immunoreactive SLC2A4 is present, but its meaning depends on whether the assay measures total protein, tissue localization, or antigen-binding signal. These readouts should not be treated as direct evidence of glucose uptake or insulin sensitivity.

• Lactocrine Insufficiency and Neonatal Uterine Development

  2026-10-26

  A porcine study linked naturally low postnatal immunoglobulin immunocrit with reduced uterine glandularity, altered FOXA2 expression, and broad transcriptional changes at postnatal day 14. The evidence supports an association between early colostrum-related exposure and neonatal uterine development, while leaving the causal contributions of antibodies, other milk-borne factors, and immune activation unresolved.

8158 records 1/544 page Next 12345 下5页 Last page